ProCE Banner Activity

postMONARCH: Abemaciclib + Fulvestrant vs Fulvestrant Monotherapy for HR+/HER2- Advanced BC After Progression on CDK4/6 Inhibitor + ET

Conference Coverage

Phase III postMONARCH demonstrated significantly improved PFS with abemaciclib plus fulvestrant vs fulvestrant monotherapy after disease progression or recurrence with CDK4/6i plus endocrine therapy in patients with HR+/HER2- advanced breast cancer.

Released: June 03, 2024

Expiration: June 02, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.


Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation